Skip to content
MatchScript
Menu

Head-to-head · The Match Score

Vaylen vs HydraMed

Both scored on the same six-factor Match Score. Vaylen wins this matchup with a 87 to 79 edge.

Higher Match Score

Vaylen

#5 · Grade B+

People who want maximum options — injectable, oral, compounded or brand — in one LegitScript-certified place.

Visit Vaylen
VS

HydraMed

#24 · Grade C

People in one of its eleven states who want a straightforward injectable program.

Visit HydraMed

Factor by factor

The six sub-scores behind each Match Score. The quiz reweights these to your priorities — one provider can pull ahead for you on the factors you care about.

Budget Fit
82
78
Speed to Start
88
74
Formulary Match
94
80
Support Level
86
82
Flexibility
86
82
Transparency
88
80

Price, coverage & formulary

DetailVaylenHydraMed
Semaglutide$179/mo$179/mo
Tirzepatide$239/mo$319/mo
CoverageAll 50 statesCO, FL, TX, TN, GA, AZ, IL, NV, VA, MD, WY
Brand-name accessYesCompounded only
Oral / sublingualYesInjectable only
Match Score87 · B+79 · C
Winner: Vaylen

Vaylen edges out HydraMed, 87 to 79 on the default Match Score. One of the widest formularies on the board — both molecules, an oral route, and brand access, all nationwide.

HydraMed is still a fair pick if its strengths line up with yours — best for: People in one of its eleven states who want a straightforward injectable program.

Worth a look either way: our overall #1 pick is CoreAge Rx (Match Score 91) — nationwide access, both molecules at one flat price, easy to cancel. Or take the 6-question quiz to see your personalized match.

Assume any provider we list may compensate us, at no cost to you. It never changes the Match Score.

Full Vaylen reviewFull HydraMed review

More head-to-heads

Or browse alternatives to Vaylen and all comparisons.

Pricing, states and verification reflect each provider's public disclosures at last review; the Match Score and its sub-scores are our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.